MXCT vs NBIX · rev $38.6M vs P/E 45, rev $2.36B
MaxCyte Inc (MXCT) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MXCT currently screens at market cap $124.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MXCT and NBIX stock pages for the full models.
Not investment advice.